Table 2 Hazard ratios (HRs)a and 95% confidence intervals for the association between metabolic syndrome (MetS) and cancer mortality
From: Metabolic dysregulation and cancer mortality in a national cohort of blacks and whites
HR (95% CI) | ||||
|---|---|---|---|---|
Black (N = 402)b | White (N = 595)b | All (N = 997)b | p valueinteraction c | |
Metabolic Syndrome | 1.32 (1.01–1.72) | 1.18 (0.94–1.48) | 1.22 (1.03–1.45) | 0.28 |
Components | ||||
High WC | 1.36 (0.75–2.46) | 1.32 (0.73–2.36) | 1.30 (0.86–1.96) | 0.07 |
Elevated Triglycerides | 0.96 (0.71–1.28) | 1.04 (0.86–1.25) | 1.00 (0.86–1.16) | 0.91 |
Reduced HDL Cholesterol | 1.30 (1.02–1.64) | 1.27 (1.03–1.55) | 1.27 (1.09–1.48) | 0.27 |
Elevated blood pressure | 1.43 (0.96–2.15) | 0.97 (0.73–1.28) | 1.11 (0.89–1.40) | 0.89 |
Elevated fasting glucose | 1.40 (1.09–1.81) | 1.02 (0.83–1.26) | 1.16 (0.99–1.36) | 0.57 |
# Metabolic Syndrome Components | ||||
0 (Referent) | Referent | Referent | Referent | 0.98 |
1 | 1.28 (0.73–2.24) | 1.09 (0.78–1.52) | 1.15 (0.86–1.53) | |
2 | 1.63 (0.92–2.88) | 1.07 (0.74–1.54) | 1.24 (0.91–1.68) | |
3 | 1.89 (1.02–3.49) | 1.23 (0.82–1.85) | 1.41 (1.01–1.97) | |
4 | 2.44 (1.26–4.74) | 1.32 (0.84–2.08) | 1.62 (1.12–2.34) | |
5 | 2.35 (1.01–5.51) | 1.36 (0.78–2.38) | 1.59 (1.01–2.51) | |